Literature DB >> 7342290

Pharmacokinetics of vancomycin in anuria.

B A Cunha, R Quintiliani, J M Deglin, M W Izard, C H Nightingale.   

Abstract

After a single 1-g intravenous dose of vancomycin, the mean peak concentration in the serum of 29 anephric patients was 48.3 micrograms/ml. An initial rapid decline to 15 micrograms/ml within 3-5 hr was followed by slow elimination, with 3.5 micrograms/ml present after 18 days. Intermittent dialysis had no appreciable effect on drug levels in serum. The biphasic decline in serum concentrations of vancomycin indicates at least two-compartment pharmacokinetics in both anephric and normal patients. In anephric patients the elimination half-life was 7.5 days and the elimination rate constant was 0.32; these values were 8 hr and 10.25, respectively, in normal patients. On the basis of these results, the vancomycin regimen recommended for anephric patients is an initial 1-g intravenous dose followed by 500 mg every eight days. With these dosages peak concentrations are 49 micrograms/ml (well below reported toxic levels) and trough concentrations are 7 micrograms/ml (well above the minimal inhibitory concentrations for susceptible pathogens causing shunt infections).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7342290

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Clostridium difficile colitis secondary to intravenous vancomycin.

Authors:  J R Hecht; E J Olinger
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

3.  Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

Authors:  J Zoer; A M Schrander-van der Meer; W T van Dorp
Journal:  Pharm World Sci       Date:  1997-08

4.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

6.  Current antibiotic usage II: Aminoglycosides, tetracyclines, erythromycin, vancomycin and sulphonamides.

Authors:  S M Merchant; N P Vithlani
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

7.  Determination of vancomycin in human serum by high-pressure liquid chromatography.

Authors:  F Jehl; C Gallion; R C Thierry; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Enhanced clearance of vancomycin by hemodialysis in a child.

Authors:  R Schoumacher; R L Chevalier; R A Gomez; A D Rogol; R Cummings; D A Spyker
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

9.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 10.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.